Pharmaceutical

TORL scores $158m in Series B2 to advance ADC cancer therapies

TORL plans to use the funds to advance the clinical development of its antibody-drug conjugate (ADC) pipeline.

Apr 11, 2024 - 00:00
TORL scores $158m in Series B2 to advance ADC cancer therapies
TORL plans to use the funds to advance the clinical development of its antibody-drug conjugate (ADC) pipeline.
Read the original article

Tags:

Previous Article

Lisata wins FDA orphan drug status for bone cancer candidate

Next Article

Acceleron Pharma gets grant for treatment of spinal muscular atrophy using ALK4:...

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

EC approves Briumvi to treat relapsing forms of multiple sclerosis

EC approves Briumvi to treat relapsing forms of multipl...

Jun 3, 2023

Vaxess raises $9m to accelerate mRNA vaccine patch development

Vaxess raises $9m to accelerate mRNA vaccine patch deve...

Sep 13, 2023

Leading innovators in ssRNA virus peptides for the pharmaceutical industry

Leading innovators in ssRNA virus peptides for the phar...

May 8, 2023